Ex­clu­sive: UPMC launch­es an­oth­er biotech, root­ed in the tu­mor mi­croen­vi­ron­ment

In Mani Mo­hin­dru’s telling, No­vasen­ta is “as biotech-y as you can get.”

The CEO of the lat­est start­up out of UPMC’s sprawl­ing re­search ap­pa­ra­tus says her biotech is look­ing for nov­el tar­gets to make new can­cer ther­a­pies, as com­pared to the pro­lif­er­a­tion of biotechs pop­ping up with pro­grams go­ing against tar­gets that are al­ready val­i­dat­ed or in the pub­lic do­main.

The com­pa­ny has se­cured $40 mil­lion in Se­ries A funds led by the Pitts­burgh in­sti­tu­tion, based on 10 years of work out of the Hill­man Can­cer Cen­ter’s Tu­mor Mi­croen­vi­ron­ment Cen­ter. Three pro­grams have been pro­pelled to cen­ter stage, with one or two of them slat­ed for IND-en­abling stud­ies lat­er next year with the aim of clin­i­cal tri­als kick­ing off in 2024, Mo­hin­dru told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER